title: [Current guidelines for treatment of dyslipidemia in kidney diseases].
abstract: Dyslipidemia is a risk factor of cardiovascular diseases and progression of chronic renal failure. Hypertriglyceridemia is the most common lipid abnormality among patients with chronic kidney disease, cholesterol levels may be high, normal or low. High triglycerides and cholesterol are observed in nephrotic syndrome, whereas cholesterol levels may be low in inflammation and malnutrition. Treatment of dyslipidemia includes modification of lifestyle, treatment of diabetes, hypertension, nephrotic syndrome, and therapy with statins in majority of patients over 50 years of age, with GFR < 60 ml/min, regardless of other risk factors of atherosclerosis. Statins decrease mortality and risk of cardio-vascular events, but have not been proven to slow down the progression of renal failure. Non- pharmacological treatment is suggested in hypertriglyceridemia > 500 mg/dl, and fibrates are not recommended, especially in combination with statins.
authors.forename: Mirosław
authors.initials: M
authors.lastname: Jędras
authors.forename: Magdalena
authors.initials: M
authors.lastname: Dylewska
mesh_terms: D050171:Dyslipidemias / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications*; D017410:Practice Guidelines as Topic
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors